Nanjing Regenecore RT2831 project was approved by the State Food and Drug Administration for clinical trials
- Categories:News
- Author:
- Origin:
- Time of issue:2024-09-12
- Views:0
Nanjing Regenecore RT2831 project was approved by the State Food and Drug Administration for clinical trials
(Summary description)Regenecore will soon carry out clinical research on RT2831 project in China.
- Categories:News
- Author:
- Origin:
- Time of issue:2024-09-12
- Views:0
On September 9, Nanjing Regenecore RT2831 project was approved by the State Food and Drug Administration for clinical trial research. This is the second regional (China) clinical trial approval document after the US Food and Drug Administration (FDA) approved the clinical trial license.
Nanjing Regenecore RT2831 project is a bispecific nanobody drug targeting specific antigens on the surface of malignant blood tumor cells, which has shown excellent safety and efficacy in non clinical studies. Nanjing Regenecore will soon carry out clinical research on RT2831 project in China.
Scan the QR code to read on your phone
TEL：
Address: Room 07 Building 16 Treehouse, No. 73, Tanmi Road, Jiangbei New District, Nanjing
Enterprise email：rjk@regenecore.com
WeChat cooperative consultation
025-58608860 
Contact 